Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. - Wikidata - awgldk - TriplyDB

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.

http://www.wikidata.org/entity/Q34328025

about

Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis Triple-negative breast cancer in African-American women: disparities versus biology.YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2.High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.Triple-negative breast cancer: new perspectives for novel therapies.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys27 acetylation in the BIM gene promoter and enhancers.Expression of EZH2 in uveal melanomas patients and associations with prognosis.Chitosan Nanoparticles for miRNA Delivery.EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.

P2860

Q27853296-A98EC970-663E-4746-853E-3603273E4545 Q33797203-FC4948C2-8C48-41DF-96CC-26015BA322AA Q34571374-1B536407-BA1D-4676-A4CD-DD66D2E1E12C Q35002412-51D98762-C90B-4A52-B0A6-5474CE659BCD Q35470183-9BCB6906-77ED-4B99-9F00-F94ACA737EA5 Q35606640-C7BFD74E-BD09-4EBA-AD69-8CD623CBDCB1 Q35941288-DED1207D-B0AD-46B6-9703-67D4C8A9CC76 Q36292201-97F89004-4046-4D5D-93B0-4EBA3BAD8997 Q36544861-DCA81C65-F477-49AD-B736-42791A60637D Q36768995-19D9BA18-03CE-4BF3-BB21-3CAA857769FF Q36836669-77429A8B-358E-4822-9E10-DBC18D319D3D Q37304764-7AD929C7-40A0-4E5C-8FFF-9A30FE7CC352 Q37422972-49E3DC20-A058-4A39-A096-04F4C0EB06E2 Q38119171-C25A93B6-1074-4A9D-81E0-207AD29B1934 Q42438922-EC9D3ADF-F00F-40B1-8E4C-31D3E729C026 Q43191053-2BF4478F-D6CF-4BD1-897B-B31E5F37BDF2 Q44045703-321A5C32-DFE6-430D-858E-3FB8DCDB1319 Q48715887-F7028A40-065F-4188-979E-1ED15DFD839D Q52325630-058272C5-2992-4868-9944-663859A75A71

P2860

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.

http://www.wikidata.org/entity/Q34328025

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Clinical and biological releva ...... triple-negative breast cancer.

@ast

Clinical and biological releva ...... triple-negative breast cancer.

@en

Clinical and biological releva ...... triple-negative breast cancer.

@nl

type

label

Clinical and biological releva ...... triple-negative breast cancer.

@ast

Clinical and biological releva ...... triple-negative breast cancer.

@en

Clinical and biological releva ...... triple-negative breast cancer.

@nl

prefLabel

Clinical and biological releva ...... triple-negative breast cancer.

@ast

Clinical and biological releva ...... triple-negative breast cancer.

@en

Clinical and biological releva ...... triple-negative breast cancer.

@nl

P1433

Q34328025-5392CC0F-B68E-4E3F-999C-328B49552340

P1476

Q34328025-DED246FA-D9AC-45C1-90C0-2DDD5BBF492D

P2093

Q34328025-0668AEBA-D312-4F6E-9875-ECC9D6359A33

Q34328025-13426B52-EBDE-44F4-A596-415C07D6E58E

Q34328025-167C42A7-F55D-4006-94FA-34B6B5694FF2

Q34328025-67847BFC-4436-44D2-A515-B1FC64493248

Q34328025-87E0C367-E647-438C-8760-7B4DF6D43F84

Q34328025-95A0083E-621E-4312-9B57-37328D77B618

Q34328025-A98FCF06-62CC-4681-AD51-FC10CCDCF65B

Q34328025-C0F1FCAA-4DC7-401A-99B8-E22AD8A3656A

Q34328025-D47E5E89-7D81-4DEA-81C3-2A9BFFDB7E38

Q34328025-F4ED576A-A816-4E5F-BF09-36AEE92A56C4

P2860

Q34328025-120B2657-4026-4AB8-A448-D0FE4134D247

Q34328025-1A96DC75-4AF6-4A89-9105-0DFEE8ACE77B

Q34328025-1D47DB69-970B-48E4-A044-EAD3E5A1646B

Q34328025-22EB100E-D7F9-429F-8C36-DF22E419BEB4

Q34328025-2646DA1B-B270-4243-A2FE-5F161BC22B1F

Q34328025-42D97CAB-36FB-4237-A5BF-02E8D66FB05B

Q34328025-50AEAB21-7B50-4EDF-839B-4D6E3E243F34

Q34328025-571FDD31-F756-4D53-A5E3-8D5935C4B56A

Q34328025-5E9B124C-106D-48BA-9ED7-6B8CC4C7B01B

Q34328025-64C1A7D9-8EF6-4724-AA92-CFE3E41ED309

P304

Q34328025-AE7877DF-9F77-4123-B73E-70D72E8E0871

P31

Q34328025-7C838E94-0841-49DC-946A-8D1E9DC47705

P356

Q34328025-A8A04E77-3269-494C-A35C-6A72132F2A01

P407

Q34328025-84D9533A-5E78-4AA8-A78F-9CCE5E9F88E5

P433

Q34328025-7D57231C-5CD8-430C-816F-7C37DB43D401

P478

Q34328025-33F0015D-FF57-440E-B0D9-2061679DBA0B

P577

Q34328025-C1EF28B2-BB17-44E3-B984-9F7FD7198BC8

P698

Q34328025-C41F86AB-3703-4163-80D3-260AF2373B8A

P932

Q34328025-9C6E5BCE-9EFC-406F-AE04-D8A2BF321476

P356

J.HUMPATH.2011.12.004

P1433

Human Pathology

P1476

Clinical and biological releva ...... triple-negative breast cancer.

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Assaad Semaan

http://www.w3.org/2001/XMLSchema#string

Bassam Albashiti

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Hee Dong Han

http://www.w3.org/2001/XMLSchema#string

Juwon Roh

http://www.w3.org/2001/XMLSchema#string

Rouba Ali-Fehmi

http://www.w3.org/2001/XMLSchema#string

Sudeshna Bandyopadhyay

http://www.w3.org/2001/XMLSchema#string

Yaser R Hussein

http://www.w3.org/2001/XMLSchema#string

Zeina Nahleh

http://www.w3.org/2001/XMLSchema#string

P2860

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

The polycomb group protein EZH2 is involved in progression of prostate cancer

Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.

Regulation of tumor angiogenesis by EZH2.

Recent advances in managing triple-negative breast cancers

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes.

P304

1638-1644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HUMPATH.2011.12.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22436627

http://www.w3.org/2001/XMLSchema#string

P932

4194857

http://www.w3.org/2001/XMLSchema#string